Skip to main content
. 2017 Aug 23;7:9229. doi: 10.1038/s41598-017-09696-y

Table 1.

Clinical and biochemical data of examined patients.

Parameter Training cohort Validation cohort P value
(n = 463) (n = 261)
Age (years) 50.14 ± 11.58 49.56 ± 10.84 0.504
Gender: female/male (n) 62/401 38/223 0.662
Family history: absent/present (n) 400/63 220/41 0.439
Drinking: absent/present (n) 245/218 153/108 0.138
Smoking: absent/present (n) 249/214 167/94 0.008
Cirrhosis: absent/present (n) 30/433 17/244 0.986
HBsAg: negative/positive (n) 68/395 45/216 0.363
HCVAb: negative/positive (n) 454/9 251/10 0.127
MaI: absent/present (n) 381/82 200/61 0.066
NγLR: median, range 137.54, 15.02–1507.96 133.59, 16.73–1236.02 0.746
SII: median, range 327.63, 5.72–2260.07 318.50, 4.35–2168.96 0.833
ALRI: median, range 24.65, 2.47–417.12 23.31, 0.94–320.96 0.540
WBC (×109/L) 6.15 ± 1.99 6.23 ± 2.00 0.598
NEUT (×109/L) 3.74 ± 1.70 3.80 ± 1.64 0.677
LYMPH (×109/L) 1.70 ± 0.63 1.72 ± 0.58 0.685
Platelets (×109/L) 175.62 ± 79.28 185.04 ± 82.63 0.131
Albumin (g/L) 39.17 ± 4.46 39.13 ± 4.34 0.915
Globulin (g/L) 30.87 ± 5.29 31.21 ± 4.96 0.388
TBIL (μmol/L) 17.82 ± 33.40 18.86 ± 41.06 0.719
DBIL (μmol/L) 7.94 ± 24.72 8.13 ± 25.05 0.850
ALT (U/L) 47.55 ± 43.51 45.39 ± 46.75 0.369
AST (U/L) 54.22 ± 55.06 53.69 ± 57.51 0.801
AFP (ng/ml): median, range 152.33, 0.23–11602.00 161.25, 0.61–10340.00 0.549
γ-GT (U/L): median, range 68.60, 10.00–657.30 67.50, 15.10–604.90 0.902
Use of NAs: absent/present (n) 310/93 181/44 0.306
Tumor size (cm) 7.82 ± 4.77 7.43 ± 4.65 0.183
Tumor number: single/multiple (n) 327/136 200/61 0.081
Tumor differentiation: I/II/III/IV (n) 61/180/178/44 43/89/91/38 0.085
Child-Pugh classification: A/B (n) 425/38 237/24 0.648
BCLC stage: 0/A/B/C (n) 20/232/116/95 18/127/78/38 0.076
Type of surgical resectiona (Anatomical/non-anatomical) 282/181 165/96 0.539

aAnatomical resection includes hemihepatectomy, sectorectomy, and segmentectomy; non-anatomical resection includes limited resection and tumor enucleation. n, number of patients; HBsAg, hepatitis B surface antigen; HCVAb, hepatitis C virus antibody; MaI, microvascular invasion; NγLR, neutrophil cell count times γ-glutamyl transpeptidase to lymphocyte count ratio; SII, systemic immune-inflammation index; ALRI, aspartate transaminase to lymphocyte ratio index; WBC, white blood cell; LYMPH, lymphocyte count; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; γ-GT, γ-glutamyl transpeptidase; NAs, nucleoside analogues; BCLC, barcelona-clinic liver cancer.